Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03470233
Other study ID # 242-402-00005
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 25, 2017
Est. completion date June 21, 2021

Study information

Verified date August 2021
Source Korea Otsuka Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Deltyba Registry aims to collect the usage information of Deltyba which could be a factor of developing resistance in actual clinical settings.


Description:

To collect the usage information of Deltyba in actual clinical settings for the management of resistance to Deltyba


Recruitment information / eligibility

Status Completed
Enrollment 149
Est. completion date June 21, 2021
Est. primary completion date June 21, 2021
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria 1. Patients who are prescribed Deltyba® per prescribing information (PI) for the purpose of treatment can be included in the registry. Exclusion Criteria 1. Patients with known hypersensitivity to Delamanid or any excipients of Deltyba® 2. Patients whose serum albumin < 2.8 g/dL 3. Patients taking medicinal products that are strong inducers of CYP3A (e.g. carbamazepine). 4. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.

Study Design


Related Conditions & MeSH terms

  • Multi-drug Resistant Tuberculosis
  • Tuberculosis
  • Tuberculosis, Multidrug-Resistant

Locations

Country Name City State
Korea, Republic of Ulsan University Hospital Ulsan
Korea, Republic of Pusan National University Yangsan Hospital Yangsan

Sponsors (1)

Lead Sponsor Collaborator
Korea Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose of Deltyba Mean values for 24 weeks
Primary Administration duration of Deltyba Mean values for 24 weeks
Primary Compliance of Deltyba percentages (%) of subjects who take Deltyba in excess of 80% compared with the amount of Deltyba prescribed by investigators for 24 weeks
Secondary Incidences of AEs Numbers (n) of subjects with AEs at least 1 month after the final administration or premature discontinuation
Secondary Incidences of ADRs Percentages (%) of subjects with ADRs at least 1 month after the final administration or premature discontinuation
Secondary Incidences of AEs in special populations Percentages (%) of subjects with AEs in special populations, such as the elderly, pregnant women, and patients with hepatic or renal disorder at least 1 month after the final administration or premature discontinuation
Secondary Incidences of ADRs in special populations Number (n) of subjects with ADRs in special populations, such as the elderly, pregnant women, and patients with hepatic or renal disorder at least 1 month after the final administration or premature discontinuation
Secondary Observed cases of resistance to Deltyba after completing the administration (Week 24) or premature discontinuation of Deltyba, Observed cases of resistance to Deltyba after 6 months of administration or discontinuation of administration Numbers (n) of subjects who developed drug resistance as determined by drug susceptibility testing (DST) to Deltyba in subjects who resulted in positive in sputum test after termination of the administration or were reverter during the course of treatment after completing the administration (Week 24) or premature discontinuation of Deltyba
Secondary Response rate Number (n) of treatment responders (sustained converters plus new converters), Numbers (n) of sustained converters, new converters, non-converters, and reverters at 24 week (at the end of Deltyba administration)
See also
  Status Clinical Trial Phase
Recruiting NCT03057756 - Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
Completed NCT04207112 - Economic Evaluation of New MDR TB Regimens Phase 2/Phase 3
Completed NCT03000517 - PK of Levofloxacin in MDR-TB Patients N/A
Completed NCT03830671 - The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB Phase 4
Withdrawn NCT01600963 - A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis Phase 3
Recruiting NCT03575299 - Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells Phase 1
Recruiting NCT03827811 - Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
Completed NCT04342598 - Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
Completed NCT04309656 - A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid Phase 1
Completed NCT03822156 - Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort
Completed NCT00425113 - Metronidazole for Pulmonary Tuberculosis (South Korea) Phase 2
Active, not recruiting NCT04081077 - PRACTECAL-PKPD Sub Study Phase 2/Phase 3
Recruiting NCT04397536 - New Genomic Techniques and Management of Multidrug-resistant Tuberculosis
Completed NCT00691392 - Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB) Phase 1/Phase 2
Completed NCT00664313 - TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB Phase 1/Phase 2